Forte Biosciences, Inc.
NASDAQ:FBRXBiotechnology
+$0.30 today
- Market cap
- $1.58B
- Beta
- 2.87
- P/E (TTM)
- -42.1
- EPS (TTM)
- -$0.43
Volume 0.00M
Average 0.30M
FBRX Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Forte Biosciences, Inc.NASDAQ: FBRX
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses grows, but more slowly than its trailing trend
Q1 FY2026 operating expenses of $22.44M rose 39.3% year over year, behind the +71.5% change in trailing-twelve-month operating expenses. Sequentially, it fell 8.8% from the prior quarter. Over 3 fiscal years it compounded at +72.0% a year.
Context
- Operating expenses increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +39.3% toward the trailing-twelve-month pace of +71.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 70.66M USD
- Year-over-year change
- +93.2%
- 4-year CAGR
- +34.7%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 70.66M | +93.2% |
| FY2024 | 2024-12-31 | 36.56M | +12.6% |
| FY2023 | 2023-12-31 | 32.48M | +133.7% |
| FY2022 | 2022-12-31 | 13.9M | -35.3% |
| FY2021 | 2021-12-31 | 21.49M | — |
Operating Expenses vs competitors
How FBRX compares with its peers on the latest reported figures
- Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +71.5% is the 3rd highest of 10, against a peer median of -13.7%.
- Over three fiscal years its annual growth of +72.0% compares with a peer median of +3.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $125.25M USD | -17.6% | -16.6% | 680.1% | |
| LTM Mar 2026 | $113.97M USD | -13.7% | -2.0% | — | |
| LTM Mar 2026 | $113.16M USD | -11.7% | -28.7% | 1791.7% | |
| LTM Mar 2026 | $89.69M USD | +109.1% | +36.8% | — | |
| LTM Mar 2026 | $79.52M USD | -27.0% | +10.5% | — | |
| LTM Mar 2026 | $76.99M USD | +71.5% | +72.0% | — | |
| LTM Mar 2026 | CHF 63.08M CHF | +100.0% | -11.3% | — | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $37.29M USD | -15.8% | +17.3% | — |
| LTM Mar 2026 | $36.37M USD | -15.3% | +7.1% | 6928.2% | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $21.83M USD | -8.1% | +3.6% | — |
| Peer median (excluding FBRX) | — | -13.7% | +3.6% | 1791.7% | |
Competitors are the stored peer set for FBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 36K | 0 | 9K | 39K | 64K |
| Gross Profit | (36K) | 0 | (9K) | (39K) | (64K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 13.85M | 5.59M | 21.86M | 21.19M | 58.25M |
| Selling, General & Admin | 7.63M | 8.3M | 10.62M | 15.37M | 12.41M |
| Operating Expenses | 21.49M | 13.9M | 32.48M | 36.56M | 70.66M |
| Depreciation & Amortization | 36K | 36K | 9K | 39K | 64K |
| EBITDA | (21.67M) | (13.84M) | (31.47M) | (35.44M) | (68.27M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (21.49M) | (13.9M) | (32.49M) | (36.6M) | (70.66M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 1.12M | 1.31M | 2.72M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (222K) | 17K | 1.01M | 1.12M | 2.32M |
| Income Before Tax | (21.71M) | (13.88M) | (31.48M) | (35.48M) | (68.34M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 1.04M |
| Net Income | (21.71M) | (13.86M) | (31.48M) | (35.48M) | (69.38M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (38.85) | (19.96) | (24.92) | (12.17) | (4.71) |
| EPS (Diluted) | (38.85) | (19.96) | (24.92) | (12.17) | (4.71) |
| Weighted Avg Shares | 558.71K | 695.34K | 1.26M | 2.92M | 147.18M |
| Weighted Avg Shares (Diluted) | 558.71K | 695.34K | 1.26M | 2.92M | 147.18M |
Forte Biosciences, Inc.
NASDAQ:FBRX
Intrinsic Alpha fair value
Locked
Current Price
$76.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.